March 6, 2009--With this release, Orion Corporation updates information provided earlier in the stock exchange release of 24 February 2009 on the regulatory implications of the results of STRIDE-PD, a clinical study aimed to provide support for extending the current EU indication of Orion's proprietary drug Stalevo® (levodopa, carbidopa and entacapone) to early Parkinson's disease. Orion has decided to withdraw its EU application for extending the indication.
The details can be read here.
No comments:
Post a Comment